22.077
Bearbeitungen
Änderungen
→Literatur
==Literatur==
==Literatur==
*[https://www.arznei-telegramm.de/html/2011_02/1102023_02.html Blutungsrisiko unter Nattokinase (DR. HITTICH NATTOPLASMIN) plus Phenprocoumon (MARCUMAR u.a.), a-t 02/2011]
*[https://www.arznei-telegramm.de/html/2011_02/1102023_02.html Blutungsrisiko unter Nattokinase (DR. HITTICH NATTOPLASMIN) plus Phenprocoumon (MARCUMAR u.a.), a-t 02/2011]
*Li X et al. (2023): Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine 24(8), 234.
*Chen H et al. (2022). Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, 9, 964977.
*Hodis HN et al. (2021): Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clin Hemorheol Microcirc.78(4): 339-353
*Gallelli G et al. (2021): Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients 13 (6): 2031
*Yoo HJ et al. (2019): The effects of nattokinase supplementation on collagen-epinephrine closure time, prothrombin time and activated partial thromboplastin time in nondiabetic and hypercholesterolemic subjects. Food Funct 10 (5): 2888-2893
*Kurosawa Y et al. (2015): A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep 5: 11601
*Liu X et al. (2023): The Effect of Nattokinase-Monascus Supplements on Dyslipidemia: A Four-Month Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 15(19): 4239
*Kim JY et al. (2008): Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res 31(8): 1583-8
*Jensen GS et al. (2016): Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control 9: 95-104
*Meixner J: Nattokinase: Studien sprechen gegen blutverdünnende Wirkung. Medizin transparent. Stand: 06.02.2024
*Harlfinger J: Vitamin K2: Schutz für die Gefäße? Medizin transparent. Stand: 13.01.2015
*Memorial Sloan Kettering Cancer Center: Nattokinase. Purposed Benefits, Side Effects & More Stand: 14.04.2022
*Verordnung (EU) Nr. 432/2012 der Kommission vom 16. Mai 2012 zur Festlegung einer Liste zulässiger anderer gesundheitsbezogener Angaben über Lebensmittel als Angaben über die Reduzierung eines Krankheitsrisikos sowie die Entwicklung und die Gesundheit von Kindern. Stand: 17.05.2021
*Blutungsrisiko unter Nattokinase (DR. HITTICH NATTOPLASMIN) plus Phenprocoumon (MARCUMAR u.a.), arznei telegramm 2011
==Weblinks==
==Weblinks==